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Abstract
Herein we present a historical review of the development of systemic chemotherapy for colorectal cancer (CRC) in the
metastatic and adjuvant treatment settings. We describe the discovery of 5-ﬂuorouracil (5-FU) by Heidelberger and
colleagues in 1957, the potentiation of 5-FU cytotoxicity by the reduced folate leucovorin, and the advent of novel
cytotoxic agents, including the topoisomerase I inhibitor irinotecan, the platinum-containing agent oxaliplatin, and the
5-FU prodrug capecitabine. The combination therapies, FOLFOX (5-FU/leucovorin and oxaliplatin) and FOLFIRI (5-FU/
leucovorin and irinotecan), have become established as efﬁcacious cytotoxic regimens for the treatment of metastatic
CRC, resulting in overall survival times of approximately 2 years. When used as adjuvant therapy, FOLFOX also im-
proves survival and is now the gold standard of care in this setting. Biological agents have been discovered that
enhance the effect of cytotoxic therapy, including bevacizumab (a humanized monoclonal antibody that targets
vascular endothelial growth factor, a central regulator of angiogenesis) and cetuximab/panitumumab (monoclonal
antibodies directed against the epidermal growth factor receptor). Despite the ongoing development of novel anti-
tumor agents and therapeutic principles as we enter the era of personalized cancer medicine, systemic chemotherapy
involving infusional 5-FU/leucovorin continues to be the cornerstone of treatment for patients with CRC.
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The most recent estimates of the worldwide burden of cancer
(GLOBOCAN 2012) indicate that colorectal cancer (CRC) is the
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11.9%), and the fourth highest cause of cancer death (694,000
deaths; 8.5%) after lung (1.59 million; 19.4%), liver (746,000;
9.1%), and stomach cancer (723,000; 8.8%).1 Despite these sta-
tistics, most patients (70%-80%) newly diagnosed with CRC have
localized disease that is amenable to curative (R0) surgical resec-
tion.2 After R0 resection, adjuvant chemotherapy with cytotoxic
agents is recommended as standard clinical practice for patients with
stage III CRC.3 This recommendation is supported by a pooled
analysis of data from the National Surgical Adjuvant Breast and
Bowel Project (NSABP) trials,4 which demonstrated signiﬁcantly
improved survival outcomes after surgery and chemotherapy
compared with surgery alone (P < .0001).
The remaining 20% to 30% of newly diagnosed patients present
with unresectable metastatic disease. In addition, a considerable
proportion of patients (40%e50%) experience disease recurrence
after surgical resection or develop metastatic disease, typically in the
liver or lungs.5 The management of patients with metastatic CRC
(mCRC) requires the systemic administration of cytotoxic drugs.3
Patients with unresectable mCRC who receive supportive care
alone have been shown to have a poor prognosis, with a medianClinical Colorectal Cancer March 2015 - 1
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2 - Clioverall survival (OS) of 5 months.6 In contrast, patients with
mCRC who receive chemotherapy have been shown to have a
median OS of > 2 years.7
Herein, we present a historical review of systemic chemotherapy
in the adjuvant and metastatic settings, highlighting the key studies
that have driven the development of chemotherapy for patients with
CRC (Figure 1).
5-Fluorouracil and Leucovorin
The German chemist Paul Ehrlich was the ﬁrst person to coin the
term ‘chemotherapy’ during his work on the use of chemical agents
to treat infectious diseases in the early 1900s.8 However, the evo-
lution of chemotherapy for CRC can be said to have begun with the
development of 5-ﬂuorouracil (5-FU) in 1957.9 Charles Hei-
delberger and colleagues at the University of Wisconsin observed
that tumor tissues preferentially used uracil for nucleic acid
biosynthesis, and correctly postulated that a ﬂuorouracil analogue
would inhibit tumor cell division by blocking the conversion of
deoxyuridine monophosphate (dUMP) to deoxythymidine mono-
phosphate (thymidylate). Biochemical studies demonstrated that the
main route of 5-FU activation proceeds via complex metabolic
pathways that result in the formation of 5-ﬂuorodeoxyuridine
monophosphate (FdUMP), a potent inhibitor of thymidylate syn-
thase (Figure 2).10-14 The level of inhibition of thymidylate synthase
achieved with FdUMP in patient tumors was shown to correlate
with the clinical response to 5-FU treatment.15,16 Studies of the
molecular mechanism of thymidylate formation identiﬁed the
transient formation of a ternary complex consisting of the substrate
dUMP, the folate cofactor 5,10-methylenetetrahydrofolate
(MTHF), and thymidylate synthase.17,18
The next key advance in the development of 5-FU-based
chemotherapy was the ﬁnding that inhibition of thymidylate syn-
thase by 5-FU could be potentiated by increased intracellular levels
of reduced folates.12,19-22 At this juncture, it is interesting to note
that the antitumor activity of folic acid analogues, including
aminopterin and amethopterin (methotrexate), was ﬁrst demon-
strated in 1948 by Sidney Farber and Louis Diamond in childrenFigure 1 Landmark Advances in the Evolution of Systemic Chemoth
Abbreviations: 5-FU ¼ 5-Fluorouracil; FOLFIRI ¼ Infusional 5-FU/LV With Irinotecan; FOLFOX ¼ 5-
Multicenter International Study of Oxaliplatin/5-FU/Leucovorin in the Adjuvant Treatment of Colon Ca
nical Colorectal Cancer March 2015with leukemia.23 The potentiation of 5-FU activity was shown to be
mediated by the formation of a stable ternary complex consisting of
FdUMP, MTHF, and thymidylate synthase.10,13,24 Polyglutamate
derivatives of MTHF were shown to substantially increase the
efﬁciency of binding of FdUMP to thymidylate synthase compared
with monoglutamate derivatives, in a human colon adenocarcinoma
xenograft25 and human Michigan Cancer Foundation-7 breast
cancer cells.26 In a pivotal in vitro study of the biomodulation of
5-FU activity by the reduced folate leucovorin (5-formyl tetrahy-
drofolate [THF]), Ullman et al19 reported that 20 mM leucovorin
enhanced 5-FU cytotoxicity approximately ﬁvefold in cultured
leukemia cells. Following on from this study, the antitumor activity
of 5-FU/leucovorin and 5-FU/methyl THF was established in a
number of studies of tumor cell lines, including those of human
origin.20,22,27-31
The preclinical data on the biomodulation of 5-FU cytotoxicity
by leucovorin led to a large number of phase I and II clinical studies
in the 1980s.32 In a pooled analysis of 21 phase II studies of patients
with advanced CRC, conducted by Poon et al in 1989, the response
rate (RR) of tumors to 5-FU/leucovorin was reported to be 23%.33
The 2 most commonly used 5-FU/leucovorin treatment regimens in
these early studies were those described by Machover et al34 and
Madajewicz et al.35 Machover et al administered 200 mg/m2 leu-
covorin using intravenous (I.V.) bolus and 370 mg/m2 5-FU in a
15-minute I.V. infusion daily for 5 days to patients with gastric
cancer and mCRC, with courses repeated at 28-day intervals.34
Madajewicz et al administered 500 mg/m2 leucovorin as a 2-hour
infusion to patients with mCRC, with escalating bolus doses of
5-FU up to a maximum of 750 mg/m2 given 1 hour after the
leucovorin infusion; this schedule was repeated weekly for 6 weeks,
followed by a 2-week rest period.35
Treatment of mCRC
In 1989, the seminal study of Michael Poon and colleagues33
showed that there was only a trend toward increased OS with
I.V. bolus 5-FU/leucovorin, but RR and progression-free survival
(PFS) were signiﬁcantly increased, compared with 5-FU alone inerapy for Patients With CRC
FU/LV With Oxaliplatin; LV ¼ Leucovorin; mCRC ¼ Metastatic Colorectal Cancer; MOSAIC ¼
ncer.
Figure 2 5-Fluorouracil (5-FU) Metabolism
Abbreviations: CDA ¼ Cytidine Deaminase; CES ¼ carboxylesterase; 50-dFCR ¼ 50-Deoxy-5-Fluorocytidine; 50-dFUR ¼ 50-Deoxy-5-Fluorouridine; DHFU ¼ Dihydroﬂuorouracil; DPYD ¼ Dihy-
dropyrimidine Dehydrogenase; DPYS ¼ Dihydropyrimidinease; FBAL ¼ Fluoro-b-Alanine; FdUDP ¼ 5-Fluorodeoxyuridine Diphosphate; FdUMP ¼ 5-Fluorodeoxyuridine Monophosphate;
FdUTP ¼ 5-Fluorodeoxyuridine Triphosphate; 5-FU ¼ 5-Fluorouracil; FUDP ¼ Fluorouridine Diphosphate; FUDR ¼ Fluorodeoxyuridine; FUMP ¼ Fluorouridine Monophosphate; FUPA ¼ Fluoro-
b-Ureidopropionate; FUR ¼ Fluorouridine; FUTP ¼ Fluorouridine Triphosphate; PPAT ¼ Phosphoribosyl Pyrophosphate Amidotransferase; RRM ¼ Ribonucleotide Reductase M; TK ¼ Thymidine
Kinase; TYMP ¼ Thymidylate Phosphorylase; TYMS ¼ Thymidylate Synthase; UCK ¼ Uridine-Cytidine Kinase; UMPS ¼ Uridine Monophosphate Synthase; UPB ¼ b-Ureidopropionase; UPP ¼ Uridine
Phosphorylase.
Adapted from Whirl-Carrillo, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92:414-7.
Bengt Gustavsson et alpatients with mCRC. Median OS was 12.2 months for patients
who received 5-FU with high-dose (200 mg/m2) leucovorin and
12.0 months for those receiving 5-FU with low-dose (20 mg/m2)
leucovorin, compared with 7.7 months for 5-FU alone (P ¼ .05,
both leucovorin doses). RRs for 5-FU with high-dose or low-dose
leucovorin were 26% (P ¼ .04) and 37% (P < .001), respec-
tively, compared with 10% for 5-FU alone. The time to progression
(TTP) rates for 5-FU with high-dose or low-dose leucovorin were
also signiﬁcantly improved compared with 5-FU alone (P ¼ .015
and P ¼ .007, respectively).
Another important study, carried out by Petrelli et al,36 demon-
strated that the RR for 5-FU with high-dose leucovorin (48%) was
signiﬁcantly greater than that with 5-FU alone (11%) or 5-FU with
methotrexate (5%; overall P ¼ .0009). In a subsequent phase III
study that compared 5-FU with high-dose or low-dose leucovorin
with 5-FU alone, Petrelli et al37 reported RRs of 12% for 5-FU alone,
30% for 5-FU with high-dose leucovorin (P < .01), and 18.8% for
5-FU with low-dose leucovorin (P ¼ not signiﬁcant [NS]).
A meta-analysis of 19 randomized trials,38 involving 3338 pa-
tients, reported a twofold increase in RR with 5-FU/leucovorin
(21%) compared with 5-FU alone (11%; P < .0001) and a smallbut statistically signiﬁcant OS beneﬁt for 5-FU/leucovorin over
5-FU alone (11.7 vs. 10.5 months, respectively; P ¼ .004).
Key developments in the early 2000s included the introduction
of the topoisomerase I inhibitor irinotecan and the platinum-
containing agent oxaliplatin as components of cytotoxic combina-
tion therapy for mCRC. Irinotecan was ﬁrst discovered and
synthesized in Japan by Yakult Honsha Ltd in 1983.39 It is a
prodrug analogue (7-ethyl-10-piperidino-piperidino-carbonyloxy
derivative) of the alkaloid camptothecin that is converted to the
active metabolite SN-38 by liver carboxylesterases.40 Oxaliplatin
was also discovered in Japan at Nagoya City University by Yoshinori
Kidani in 1976 by testing the antitumor activity of various platinum
(II) complexes of 1,2-diaminocyclohexane isomers.41
Saltz et al42 found that treatment with bolus 5-FU/leucovorin
and irinotecan (IFL) resulted in signiﬁcantly longer PFS (7.0 vs. 4.3
months; P ¼ .004), greater RR (39% vs. 21%; P < .001), and
longer OS (14.8 vs. 12.6 months; P ¼ .04) than 5-FU/leucovorin
alone as ﬁrst-line therapy for patients with mCRC. In the Inter-
group trial N9741,43 the efﬁcacy of FOLFOX (5-FU/leucovorin
with oxaliplatin) was signiﬁcantly better than that of IFL with re-
gard to OS (19.5 vs. 15.0 months, respectively; P < .0001), TTPClinical Colorectal Cancer March 2015 - 3
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4 - Cli(8.7 vs. 6.9 months; P ¼ .0014), and RR (45% vs. 31%; P ¼ .002).
The FOLFOX regimen was also associated with signiﬁcantly lower
rates of severe nausea, vomiting, diarrhea, and febrile neutropenia
than was the IFL regimen (all P < .001). The unfavorable toxicity
proﬁle of the IFL regimen led to the development of a regimen
comprised of infusional IFL (FOLFIRI). The GOIM (Gruppo
Oncologico Dell’Italia Meridionale) study44 and the GERCOR
(Groupe Coopérateur Multidisciplinaire en Oncologie) crossover
study45 each showed similar efﬁcacy for the FOLFIRI and FOL-
FOX regimens. The GOIM study reported RRs of 31% and 34%
(P ¼ NS), OS rates of 14 and 15 months (P ¼ NS), and median
TTPs of 7 months (both, P ¼ NS) for FOLFIRI and FOLFOX,
respectively. The GERCOR study demonstrated OS rates of 21.5
months in patients allocated to FOLFIRI then FOLFOX, and 20.6
months in those treated with FOLFOX then FOLFIRI (P ¼ NS).
As ﬁrst-line therapy, FOLFIRI achieved an RR of 56% and PFS of
8.5 months, and for FOLFOX the RR was 54% (P ¼ NS) and the
PFS was 8.0 months (P ¼ NS).
The combination of infusional 5-FU/leucovorin, oxaliplatin, and
irinotecan (FOLFOXIRI) was compared with FOLFIRI in 2 ran-
domized, phase III trials. Souglakos et al46 reported no signiﬁcant
differences in OS, TTP, or RR between the 2 treatment regimens.
Falcone et al47 showed a signiﬁcantly greater RR for patients treated
with FOLFOXIRI than for those treated with a modiﬁed FOLFIRI
regimen containing 400 to 600 mg/m2 5-FU (60% vs. 34%,
respectively; P < .0001). PFS (9.8 vs. 6.9 months; P ¼ .0006) and
OS (22.6 vs. 16.7 months; P ¼ .032) were also signiﬁcantly
improved in the FOLFOXIRI arm compared with in the modiﬁed
FOLFIRI arm, but at the cost of a signiﬁcant (P < .001) increase in
toxicity, in terms of increased grades of peripheral neurotoxicity
(P < .001) and neutropenia (P < .001).
The idea of targeting angiogenesis as an anticancer therapy was
ﬁrst proposed by Judah Folkman and colleagues in 1971.48 How-
ever, it was not until 2004 that the pivotal Avastin/Fluorouracil
2107 phase III trial49 evaluated the humanized monoclonal anti-
body bevacizumab, which inhibits the action of vascular endothelial
growth factor. In this trial, patients were randomized to IFL with
bevacizumab or IFL alone. The addition of bevacizumab signiﬁ-
cantly improved OS (20.3 vs. 15.6 months, respectively; P < .001),
PFS (10.6 vs. 6.2 months; P < .001), and RR (44.8% vs. 34.8%;
P ¼ .004) compared with IFL alone. In another key trial, the
Eastern Cooperative Oncology Group 3200 study50 enrolled pa-
tients previously treated with IFL and found that OS (12.9 vs. 10.8
months, respectively; P < .0011), PFS (7.3 vs. 4.7 months; P <
.0001), and RR (22.7% vs. 8.6%; P < .0001) were all signiﬁcantly
improved with bevacizumab and FOLFOX treatment compared
with FOLFOX alone.
In 1983 and 1984, John Mendelsohn and Gordon Sato and
colleagues proposed epidermal growth factor receptor (EGFR) as a
novel target for cancer therapy, based on observations that EGFR
was frequently overexpressed in epithelial tumors and that
monoclonal antibodies directed against EGFR inhibited the
growth of cancer cells.51-54 The anti-EGFR monoclonal antibodies
cetuximab and panitumumab were the ﬁrst therapeutic agents
targeted at a speciﬁc molecular pathology: EGFR-positive tumors
expressing wild type Kirsten rat sarcoma viral oncogene homolog
(KRAS).55 The efﬁcacy of cetuximab in the treatment of patientsnical Colorectal Cancer March 2015with mCRC was evaluated in the CRYSTAL (Cetuximab Com-
bined with Irinotecan in First-Line Therapy for Metastatic Colo-
rectal Cancer) study,56,57 in which patients with EGFR-positive
tumors were randomized to receive FOLFIRI alone or FOLFIRI
with cetuximab. FOLFIRI with cetuximab marginally improved
PFS compared with FOLFIRI alone (8.9 vs. 8.0 months, respec-
tively; P ¼ .048), but there was no signiﬁcant difference in OS
between the 2 treatments (19.9 vs. 18.6 months; P ¼ NS). In a
subset analysis of patients with wild type KRAS (63%), FOLFIRI
with cetuximab signiﬁcantly improved OS (23.5 vs. 20.0 months;
P ¼ .01), PFS (9.9 vs. 8.4 months; P ¼ .001), and RR (57.3% vs.
39.7%; P ¼ .001) compared with FOLFIRI alone. No signiﬁcant
difference in efﬁcacy was evident in patients with mutant KRAS.
In the PRIME (Panitumumab Randomized Trial in Combina-
tion With Chemotherapy for Metastatic Colorectal Cancer to
Determine Efﬁcacy) trial,58 patients were randomized to treatment
with FOLFOX with or without panitumumab, regardless of EGFR
or KRAS status. In the subset with wild type KRAS (60% of the
study population), panitumumab with FOLFOX signiﬁcantly
improved PFS compared with FOLFOX alone (9.6 vs. 8.0 months,
respectively; P ¼ .02), but did not lead to a signiﬁcant improvement
in OS (23.9 vs. 19.7 months; P ¼ NS).
The UK Medical Research Council (MRC) Continuous
Chemotherapy Plus Cetuximab or Intermittent Chemotherapy trial
was a 3-arm randomized controlled trial in which patients were
randomized to receive continuous FOLFOX, continuous FOLFOX
with cetuximab, or intermittent FOLFOX alone. Maughan et al59
reported the results for 2 of these regimens: FOLFOX with cetux-
imab increased RR compared with FOLFOX alone (59% vs. 50%,
respectively; P ¼ .015), but there was no evidence of improved PFS
or OS in patients with wild type KRAS.
Patients in the Nordic-VII study60 were randomized to receive
Nordic FLOX (bolus FOLFOX), Nordic FLOX with cetuximab, or
intermittent Nordic FLOX with cetuximab. OS, PFS, and RR were
similar in the 3 treatment arms (OS: 20.4, 19.7, and 20.3 months,
respectively [P ¼ NS]; PFS: 7.9, 8.3, and 7.3 months [P ¼ NS];
and RR: 41%, 49%, and 47% [P ¼NS]). In patients with wild type
KRAS, cetuximab did not provide any additional beneﬁt compared
with Nordic FLOX alone for PFS, OS, or RR.
Findings of several key studies presented at the 2013 Annual
Meeting of the American Society of Clinical Oncology (ASCO)
provided important updates to the current picture. In the FIRE-3
(FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as
ﬁrst-line treatment for patients with metastatic colorectal cancer)
trial,61 patients with wild type KRAS were randomized to receive
ﬁrst-line FOLFIRI with cetuximab or FOLFIRI with bev-
acizumab. The primary end points of overall RR (62% vs. 58%,
respectively) and PFS (10.0 vs. 10.3 months, respectively) were
not signiﬁcantly different in the 2 treatments arms. However,
FOLFIRI with cetuximab provided a statistically signiﬁcant
improvement in OS compared with FOLFIRI with bevacizumab
(28.7 vs. 25.0 months, respectively; P ¼ .017). A further impor-
tant contribution to the ongoing ﬁrst-line therapy debate in
mCRC was the TRIBE (Combination Chemotherapy and Bev-
acizumab as First-line Therapy in Treating Patients with Meta-
static Colorectal Cancer) trial.62 This trial, which evaluated
FOLFOXIRI and bevacizumab versus FOLFIRI and bevacizumab,
Bengt Gustavsson et alshowed a signiﬁcant difference in the primary end point of PFS
(12.1 vs. 9.7 months, respectively; P ¼ .006). The phase II PEAK
(Panitumumab Efﬁcacy in Combination with mFOLFOX6Table 1 Key Clinical Studies in the Development of Therapy for Pat
Study
Publication
Date Study Objective
5-FU/LV
Petrelli et al36 1987 To compare the efﬁcacy of 5-FU with high
(500 mg/m2), 5-FU with methotrexate, and
Petrelli et al37 1989 To determine whether 5-FU with high-dose (
or low-dose (25 mg/m2) LV increases e
compared with 5-FU alone
Poon et al33 1989 To evaluate the efﬁcacy of 5-FU with hi
(200 mg/m2) LV, 5-FU with low-dose (20
LV, and 5-FU alone
5-FU/LV, IFL
Saltz et al.42 2000 To compare the efﬁcacy of IFL versus 5-FU
FOLFOX, IFL
Intergroup N974143 2004 To compare the efﬁcacy and toxicity of
versus IFL regimens
FOLFIRI, FOLFOX
GERCOR45 2004 A crossover study to investigate the ef
of FOLFIRI followed by FOLFOX versus F
followed by FOLFIRI
GOIM44 2005 To compare the efﬁcacy of FOLFIRI v
FOLFOX regimens
FOLFIRI, FOLFOXIRI
Souglakos et al46 2006 To compare the efﬁcacy and toxicity of
versus FOLFOXIRI regimens
Falcone et al47 2007 To compare the efﬁcacy and toxicity of F
versus FOLFIRI regimens
Bevacizumab
AVF 210749 2004 To determine whether bevacizumab with IF
survival versus IFL alone
ECOG 320050 2007 To determine the effect of bevacizumab wi
on survival duration versus FOLFOX a
Cetuximab,
Panitumumab
CRYSTAL56,57 2009, 2011 To investigate the efﬁcacy of cetuximab wi
versus FOLFIRI alone; and the association
tumor KRAS mutation status and clinical
to cetuximab
PRIME58 2010 To evaluate the efﬁcacy and safety of pan
with FOLFOX versus FOLFOX alon
COIN59 2011 To assess the efﬁcacy of cetuximab with
versus FOLFOX aloneAgainst Bevacizumab plus mFOLFOX6 in mCRC Subjects with
Wild-Type KRAS Tumors) trial63 randomized patients with wild
type rat sarcoma (KRAS or neuroblastoma rat sarcoma) to ﬁrst-lineients With mCRC
Patients
(n) Key Efﬁcacy Results
-dose LV
5-FU alone
74 OS: 12, 10, 11 months, respectively (P ¼ NS)
RR: 48%, 5%, 11%, respectively (P ¼ .0009)
500 mg/m2)
fﬁcacy
343 OS: 13.8, 11.3, 11.5, months, respectively (P ¼ NS)
RR: 30%, 19%, 12%, respectively (P < .01)
gh-dose
mg/m2)
429 OS: 12.2, 12.0, 7.7 months, respectively
(adjusted P ¼ .05, both LV doses)
RR: 26% (P ¼ .04), 37% (P < .001),
10%, respectively
/LV alone 683 OS: 14.8 versus 12.6 months (P ¼ .04)
PFS: 7.0 versus 4.3 months (P ¼ .004)
RR: 39% versus 21%; (P < .001)
FOLFOX 795 OS: 19.5 versus 15.0 months (P < .0001)
TTP: 8.7 versus 6.9 months (P ¼ .0014)
RR: 45% versus 31% (P ¼ .002)
ﬁcacy
OLFOX
222 OS: 21.5 versus 20.6 months (P ¼ NS)
PFS: 8.5 versus 8.0 months (P ¼ NS)
RR: 56% versus 54% (P ¼ NS)
ersus 360 OS: 14 versus 15 months (P ¼ NS)
RR: 31% versus 34% (P ¼ NS)
TTP: 7 versus 7 months (P ¼ NS)
FOLFIRI 283 OS: 19.5 versus 21.5 months (P ¼ NS)
TTP: 6.9 versus 8.4 months (P ¼ NS)
RR: 34% versus 43% (P ¼ NS)
OLFOXIRI 244 OS: 22.6 versus 16.7 months (P ¼ .032)
RR: 60% versus 34% (P < .0001)
PFS: 9.8 versus 6.9 months (P ¼ .0006)
L improves 813 OS: 20.3 versus 15.6 months (P < .001)
PFS: 10.6 versus 6.2 months (P < .001)
RR: 44.8% versus 34.8% (P ¼ .004)
th FOLFOX
lone
829 OS: 12.9 versus 10.8 months; (P < .0011)
PFS: 7.3 versus 4.7 months (P < .0001)
RR: 22.7% versus 8.6% (P < .0001)
th FOLFIRI
between
response
1198 OS: 19.9 versus 18.6 months (P ¼ NS)
PFS: 8.9 versus 8.0 months (P ¼ .048).
In patients with wild type KRAS (63%),
OS: 23.5 versus 20.0 months (P ¼ .01)
PFS: 9.9 versus 8.4 months (P ¼ .001)
RR: 57.3% versus 39.7% (P ¼ .001)
No signiﬁcant difference in efﬁcacy was evident
in patients with mutant KRAS
itumumab
e
1183 In patients with wild type KRAS (60%)
OS: 23.9 versus 19.7 months (P ¼ NS)
PFS: 9.6 versus 8.0 months (P ¼ .02)
FOLFOX 1630 OS: 17.0 versus 17.9 months (P ¼ NS)
RR: 59% versus 50% (P ¼ .015)
No evidence of improved PFS or OS in patients
with wild type KRAS
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Table 1 Continued
Study
Publication
Date Study Objective
Patients
(n) Key Efﬁcacy Results
Nordic-VII60 2012 To investigate the efﬁcacy of Nordic FLOX, cetuximab
with Nordic FLOX, and cetuximab with intermittent
Nordic FLOX
571 OS: 20.4, 19.7, 20.3 months, respectively (P ¼ NS)
PFS: 7.9, 8.3, 7.3 months, respectively (P ¼ NS)
RR: 41%, 49%, 47%, respectively (P ¼ NS)
In patients with KRAS mutations, no signiﬁcant
differences were detected
Abbreviations: AVF ¼ Avastin/Fluorouracil; COIN ¼ Continuous Chemotherapy with Cetuximab or Intermittent Chemotherapy; CRYSTAL ¼ Cetuximab Combined with Irinotecan in First-Line Therapy for
Metastatic Colorectal Cancer; ECOG ¼ Eastern Cooperative Oncology Group; FLOX ¼ bolus 5-FU/LV with oxaliplatin; FOLFIRI ¼ infusional 5-FU/LV with irinotecan; FOLFOX ¼ 5-FU/LV with oxaliplatin;
FOLFOXIRI ¼ 5-FU/LV with oxaliplatin and irinotecan; 5-FU ¼ 5-ﬂuorouracil; GERCOR ¼ Groupe Coopérateur Multidisciplinaire en Oncologie; GOIM ¼ Gruppo Oncologico dell’Italia Meridionale;
IFL ¼ bolus 5-FU/LV with irinotecan; KRAS ¼ Kirsten rat sarcoma viral oncogene homolog; LV ¼ leucovorin; mCRC ¼ metastatic colorectal cancer; NS ¼ nonsigniﬁcant; OS ¼ overall survival;
PFS ¼ progression-free survival; PRIME ¼ Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efﬁcacy; RR ¼ response rate;
TTP ¼ time to progression.
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6 - Clipanitumumab with FOLFOX or bevacizumab with FOLFOX.
PFS for panitumumab with FOLFOX was 13.1 months, com-
pared with 9.5 months for bevacizumab with FOLFOX (P ¼ .02).
OS for the panitumumab arm was not reached at the time of
reporting, but was 29 months for the bevacizumab arm. At ASCO
2012, PEAK data were reported, which suggested that the pan-
itumumab regimen had an adverse effect on PFS in patients with
mutated compared with wild type KRAS, although the effect was
not signiﬁcant (15.5 vs. 19.3 months, respectively; P ¼ NS).64
Although not validated, the PEAK results suggest that pan-
itumumab should not be used for the treatment of mCRC in
patients with KRAS mutations or in whom the KRAS status is
unknown.
Orally administered 5-FU prodrugs were developed to provide a
convenient alternative to treatment regimens requiring I.V. infusion
of 5-FU. An example of such an oral regimen is the combination of
uracil and the 5-FU prodrug tegafur in a 4:1 molar ratio (UFT).
Uracil competitively inhibits dihydropyrimidine dehydrogenase, the
main catabolic enzyme of 5-FU (Figure 2). In a meta-analysis of 5
randomized controlled trials that compared UFT/leucovorin with
bolus 5-FU/leucovorin, Bin et al65 reported that there were no
signiﬁcant differences in OS and RR between the 2 regimens;
however, UFT/leucovorin had a signiﬁcantly lower toxicity rate
than bolus 5-FU/leucovorin (P < .001 for stomatitis/mucositis,
Grade 1-4 leukopenia, febrile neutropenia, and infection). These
ﬁndings are consistent with a pooled efﬁcacy analysis from 2 phase
III studies that compared capecitabine (another oral 5-FU prodrug)
with bolus 5-FU/leucovorin.66 A statistically signiﬁcant difference
in RR was reported for capecitabine compared with 5-FU and
leucovorin (26% vs. 17%, respectively; P < .0002), whereas OS
(12.9 vs. 12.8 months; P ¼ NS) and TTP (4.6 vs. 4.7 months; P ¼
NS) were equivalent in the 2 treatment groups. In Table 1 the
ﬁndings of the key mCRC studies described in this section are
summarized.33,36,37,42-47,49,50,56-60 Figure 3 shows the temporal
trend of OS in these studies. It can be seen that median OS
increased sharply from 12.0 months in the early studies of Petrelli
et al36 and Poon et al,33 to 21.5 months in the GERCOR study,45
and except for the GOIM study,44 has remained at 18 to 24 months
in recent, large phase III trials.
Adjuvant Treatment of CRC
In the 1970s and 1980s, the antihelminthic drug levamisole
attracted interest as a possible chemotherapeutic agent because of itsnical Colorectal Cancer March 2015putative immunomodulatory activity.67,68 In 1989, the North
Central Cancer Treatment Group (NCCTG) reported that treat-
ment with levamisole with 5-FU led to a signiﬁcant reduction
in cancer recurrence (P ¼ .003) and a signiﬁcant increase in OS
(P ¼ .03) when compared with no adjuvant therapy.69 In 1990,
Charles Moertel and colleagues70 published the results of their
seminal study of the efﬁcacy of 5-FU with levamisole versus no
adjuvant therapy in patients with stage II or III CRC. 5-FU with
levamisole reduced the risk of cancer recurrence by 41% (P <
.0001) and the overall death rate by 33% (P ¼ .006) compared
with observation alone. Interestingly, treatment with levamisole
alone had no effect. These ﬁndings led to the acceptance of 5-FU
with levamisole as the standard adjuvant therapy in the 1990s.71
The next stage in the evolution of adjuvant therapy involved the
evaluation of 5-FU with leucovorin in several key trials. The
NSABP C-03 study72 reported a 3-year disease-free survival (DFS)
rate of 73% for patients receiving 5-FU/leucovorin, compared with
a rate of 64% for those who received a combination of the alkylating
nitrosourea lomustine, the alkaloid vincristine, and 5-FU (MOF;
P ¼ .0004). The IMPACT (International Multicenter Pooled
Analysis of Colorectal Cancer Trials)73 pooled data from 3 ran-
domized trials that investigated high-dose 5-FU/leucovorin
compared with no adjuvant therapy. 5-FU/leucovorin reduced
mortality by 22% (P ¼ .029) and CRC events by 35% (P < .0001)
compared with no adjuvant therapy.
A number of randomized trials evaluated the efﬁcacy and safety
of the most commonly used 5-FU/leucovorin treatment regimens
in the adjuvant setting. The intergroup-0089 study74 set out to
evaluate 4 regimens: (1) the Mayo Clinic regimen, comprised of a
daily 20 mg/m2 (low-dose) I.V. bolus of leucovorin and 425 mg/
m2 I.V. bolus of 5-FU for 5 consecutive days, repeated every 4 to 5
weeks; (2) the Roswell Park regimen, consisting of a weekly 500
mg/m2 (high-dose) I.V. bolus of leucovorin and 500 mg/m2 I.V.
bolus of 5-FU for 6 weeks, repeated every 8 weeks; (3) low-dose
5-FU/leucovorin with levamisole; and (4) levamisole alone. The
main ﬁnding was that there were no statistically signiﬁcant differ-
ences among the treatment arms in DFS (9.4, 7.9, 9.2, and 7.1
months, respectively) or OS (11.5, 10.7, 11.4, and 10.3 months,
respectively). The MRC study75 evaluated 3 months of continuous
infusion of 5-FU and a 6-month course of the Mayo Clinic
regimen. There was no statistically signiﬁcant difference between
the 2 arms in terms of OS (87.9% vs. 83.2%, respectively;
P ¼ NS). However, patients in the Mayo Clinic regimen arm had
Figure 3 Temporal Trend of Median Overall (OS) Survival in Key Metastatic Colorectal Cancer Clinical Trials. The OS Values Shown for
Each Study Represent the Treatment Arm With the Longest Median Survival
Abbreviations: AFV ¼ Avastin/Fluorouracil; COIN ¼ Continuous Chemotherapy With Cetuximab or Intermittent Chemotherapy; CRYSTAL ¼ Cetuximab Combined With Irinotecan in First-Line Therapy
for Metastatic Colorectal Cancer; GERCOR ¼ Groupe Coopérateur Multidisciplinaire en Oncologie; GOIM ¼ Gruppo Oncologico dell’Italia Meridionale; PRIME ¼ Panitumumab Randomized Trial in
Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efﬁcacy.
Bengt Gustavsson et alsigniﬁcantly lower rates of PFS compared with those who received
continuous infusion 5-FU (69% vs. 80%, respectively; P ¼ .02).
In terms of safety, the frequency of Grade 3 or 4 neutropenia,
diarrhea, stomatitis, and severe alopecia were signiﬁcantly lower
(P < .0001), and global quality of life scores signiﬁcantly better
(P < .001), for patients in the continuous infusion arm compared
with the Mayo Clinic regimen arm. The GERCOR C96.1 study76
compared the Mayo Clinic regimen with LV5FU2 (twice-monthly
I.V. infusion of 5-FU/leucovorin; de Gramont regimen77). There
were no statistically signiﬁcant differences between the 2 arms in
terms of DFS (P ¼ NS) or OS (P ¼ NS), but the de Gramont
regimen was signiﬁcantly less toxic than the Mayo Clinic regimen
(P ¼ .001).
In the X-ACT (Xeloda in Adjuvant Colon Cancer Therapy)
trial,78 patients were randomized to capecitabine or the Mayo Clinic
regimen. There were no statistically signiﬁcant differences between
the 2 arms in terms of DFS (64.2% vs. 60.6%, respectively; P ¼
NS) or OS (81.3% and 77.6%; P ¼ .05). However, capecitabine
was associated with signiﬁcantly fewer adverse events than the Mayo
Clinic regimen (P < .001). The NSABP C-06 study,79 which
compared tegafur with leucovorin versus the Roswell Park regimen,
reported that 5-year DFS (68.2% vs. 67.0%, respectively; P ¼ NS)
and OS (78.7% vs. 78.5%; P ¼ NS) were similar for the 2
treatments.
In 2004, an interim analysis of data from the pivotal MOSAIC
(Multicenter International Study of Oxaliplatin/5-FU/Leucovorin
in the Adjuvant Treatment of Colon Cancer) trial80 showed thatFOLFOX signiﬁcantly improved 3-year DFS compared with 5-FU/
leucovorin (FL regimen: 2-hour I.V. infusion of 200 mg/m2 of
leucovorin followed by an I.V. bolus of 400 mg/m2 of 5-FU and
then a 22-hour I.V. infusion of 600 mg/m2 of 5-FU given on 2
consecutive days every 14 days); FOLFOX, 78.2% versus FL,
72.9%, respectively (P ¼ .002) in patients with stage III CRC,
although neutropenia (Grades 3 and 4) was signiﬁcantly more
frequent with FOLFOX than with FL (41.1% vs. 4.7%; P < .001).
The ﬁnal analysis of data from MOSAIC in 200981 conﬁrmed
statistically signiﬁcant improvements in DFS and OS for FOLFOX
compared with FL (5-year DFS: 73.3% vs. 67.4%, respectively
[P ¼ .003] and 6-year OS: 78.5% vs. 76.0% [P ¼ .046]). No
survival beneﬁt was detected in patients with stage II disease. The
MOSAIC ﬁndings established FOLFOX as the standard adjuvant
therapy for resected stage III CRC, and, in so doing, suggested that
treatments with proven efﬁcacy in the management of mCRC could
also be effective in the adjuvant setting. Unfortunately, negative
results from a number of large multicenter trials have shown these
hopes to be unfounded.
The PETACC (Pan-European Trial in Adjuvant Colorectal
Cancer)-382 compared FOLFIRI and 5-FU/leucovorin (de
Gramont regimen) in patients with stage III disease. FOLFIRI did
not produce signiﬁcant improvements compared with 5-FU/leu-
covorin in either DFS (56.7% vs. 54.3%, respectively; P ¼ NS) or
OS (73.6% vs. 71.3%; P ¼ NS). These ﬁndings corroborated
those of the Cancer and Leukemia Group B (CALGB) 8980383
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Table 2 Key Clinical Studies in the Development of Adjuvant Therapy for Patients With CRC
Study
Publication
date Study Objective
Patients
(n) Key Efﬁcacy Results
5-FU With
Levamisole
Moertel et al70 1990 To compare the efﬁcacy of 5-FU with levamisole versus
observation only in patients with stage II or III CRC
1296 3.5-Year OS: 71% versus 55%
Cancer recurrence rate: 41% (P < .0001)
Overall death rate: 33% (P ¼ .006)
5-FU/LV
NSABP C-0372 1993 To evaluate the efﬁcacy of 5-FU/LV versus MOF in
patients with stage II or III CRC
1081 3-Year OS: 84% versus 77% (P ¼ .007)
IMPACT73 1995 Pooled analysis of 3 randomized trials to investigate the
efﬁcacy of high-dose 5-FU/LV versus no adjuvant
therapy in patients with stage II or III CRC
1493 3-Year OS: 83% versus 78%
Overall death rate: 22% (P ¼ .029)
CRC events: 35% (P < .0001)
INT-008974 2005 To assess the relative efﬁcacy of 5-FU/LV (Mayo Clinic
regimen), 5-FU/LV (Roswell Park regimen), Mayo Clinic
regimen with levamisole, and 5-FU with levamisole in
patients with stage II or III CRC
3794 5-Year OS: 66%, 66%, 64%, and 54%
(P ¼ NS)
X-ACT78 2005 To evaluate the efﬁcacy of capecitabine versus 5-FU/LV
(Mayo Clinic regimen) in patients with stage III CRC
1987 3-Year OS: 81% versus 78% (P ¼ .05)
3-Year DFS: 64% versus 61% (P ¼ NS)
NSABP C-0679 2006 To compare the efﬁcacy of tegafur with LV versus 5-FU/LV
(Roswell Park regimen) in patients with stage II or III CRC
1608 5-Year OS: 79% versus 79% (P ¼ NS)
5-Year DFS: 68% versus 67% (P ¼ NS)
GERCOR C96.176 2007 To compare the efﬁcacy of the de Gramont versus Mayo
Clinic regimens of 5-FU/LV in patients with stage II or III CRC
905 6-Year OS: 76% versus 78% (P ¼ NS)
6-Year DFS: 66% versus 65% (P ¼ NS)
FOLFOX, FOLFIRI
MOSAIC80,81 2004, 2009 To evaluate the efﬁcacy of FOLFOX versus 5-FU/LV in
patients with stage II or III CRC
2246 6-Year OS: 79% versus 76% (P ¼ .046)
5-Year DFS: 73% versus 67% (P ¼ .003)
PETACC-382 2009 To investigate the efﬁcacy of FOLFIRI versus the de Gramont
5-FU/LV regimen in patients with stage III CRC
2094 5-Year OS: 73.6% versus 71.3% (P ¼ NS)
5-Year DFS: 56.7% versus 54.3% (P ¼ NS)
Bevacizumab
NSABP C-0885 2011 To investigate the efﬁcacy and safety of bevacizumab with
FOLFOX versus FOLFOX in patients with stage II or III CRC
2672 3-Year DFS: 77% versus 76% (P ¼ NS)
Cetuximab
NCCTG/Intergroup
N014786
2012 To assess the beneﬁt of cetuximab with mFOLFOX6 versus
mFOLFOX6 in wild type KRAS patients with stage III CRC
2686 3-Year OS: 87% versus 86% (P ¼ NS)
3-Year DFS: 75% versus 72% (P ¼ NS)
(prespeciﬁed interim analysis)
Abbreviations: CRC ¼ colorectal cancer; DFS ¼ disease-free survival; FOLFIRI ¼ infusional 5-FU/LV with irinotecan; FOLFOX ¼ 5-FU/LV with oxaliplatin; 5-FU ¼ 5-ﬂuorouracil; GERCOR ¼ Groupe
Coopérateur Multidisciplinaire en Oncologie; IMPACT ¼ International Multicentre Pooled Analysis of Colorectal Cancer Trials; INT ¼ intergroup; KRAS ¼ Kirsten rat sarcoma viral oncogene homolog;
LV ¼ leucovorin; mFOLFOX6 ¼ modiﬁed FOLFOX; MOF ¼ 5-FU with lomustine and vincristine; MOSAIC ¼ Multicenter International Study of Oxaliplatin/5-FU/Leucovorin in the Adjuvant Treatment of
Colon Cancer; NCCTG ¼ North Central Cancer Treatment Group; NS ¼ nonsigniﬁcant; NSABP ¼ National Surgical Adjuvant Breast and Bowel Project; OS ¼ overall survival; PETACC ¼ Pan-European
Trial in Adjuvant Colorectal Cancer; X-ACT ¼ Xeloda in Adjuvant Colon Cancer Therapy.
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8 - Cli(ACCORD) 0284 trials. The CALGB study reported that there
was no signiﬁcant difference in 3-year DFS, the primary end point
of the trial, between 5-FU/leucovorin and IFL (60% vs. 63%,
respectively; P ¼ NS). The main ACCORD02 ﬁndings were that
5-year OS rates for 5-FU/leucovorin and FOLFIRI were 67% and
61%, respectively (P ¼ NS), and 3-year DFS rates were 60% and
51% (P ¼ NS).
Much effort has been expended in investigating the efﬁcacy of
bevacizumab and cetuximab in the adjuvant setting. In the NSABP
C-08 trial,85 carried out in patients with stage II or III CRC,
treatment with FOLFOX with bevacizumab showed no signiﬁcant
improvement in 3-year DFS compared with FOLFOX alone
(77.4% vs. 75.5%, respectively; P ¼ NS). In the NCCTG/Inter-
group N0147 trial,86 patients with resected stage III CRC and wild
type KRAS were randomly assigned to receive mFOLFOX6
(modiﬁed FOLFOX) with cetuximab or mFOLFOX6 alone.
The trial was terminated when the prespeciﬁed interim analysisnical Colorectal Cancer March 2015demonstrated that there was no beneﬁt in terms of the primary end
point of 3-year DFS from the addition of cetuximab to mFOL-
FOX6 (74.6% with mFOLFOX6 alone vs. 71.5% with mFOL-
FOX6 with cetuximab; P ¼ NS). In Table 2 the ﬁndings of the key
adjuvant studies described in this section are summarized.
Conclusions
The evolution of chemotherapy for patients with CRC has
involved a series of landmark advances, including the discovery of
5-FU, the identiﬁcation of the reduced folate leucovorin as a
clinical potentiator of 5-FU cytotoxicity, and the advent of novel
cytotoxic and biological agents. As we move into the era of
personalized cancer medicine, systemic chemotherapy involving
infusional 5-FU/leucovorin remains the cornerstone of treatment
for patients with CRC, but there is a need for empirical studies to
explore how current treatment regimens can be optimized for
individual patients.
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